Synovial chondromatosis is a condition in which cartilage nodules form in the lining of a joint. Some may detach and become loose bodies, causing pain, swelling or locking. It needs a structural diagnosis and an appropriate orthopaedic plan, rather than an injection selected only because the knee hurts.
The condition is uncommon, and many more common problems can produce similar symptoms. Ask about a diagnosis-led knee assessment if you have an imaging report mentioning loose bodies or synovial chondromatosis. Bring the scan and report so that the question is what needs treating, not simply whether PRP is available.
What happens inside the joint?
The synovium is the thin tissue lining the joint. In synovial chondromatosis, cartilage nodules develop within it. These can grow, harden or form bone, and some break away into the joint space.
The American Academy of Orthopaedic Surgeons distinguishes primary disease, a rare benign tumour of the synovium, from secondary nodules associated with underlying joint damage such as arthritis or trauma. The distinction matters because treatment needs to address the actual process.
Benign does not mean that the joint can safely be ignored. Nodules can damage the cartilage, and a loose body can interfere with movement. The condition is most often found in the knee, but other joints can be affected.
Which symptoms can it cause?
Joint pain, recurrent swelling and stiffness can resemble arthritis. Some people notice grinding, catching, giving way or episodes in which the knee seems to stick. These features are reasons to investigate, not a diagnosis by themselves.
A genuinely locked knee or inability to bear weight after an injury needs prompt medical assessment. A hot swollen joint with fever or feeling seriously unwell needs urgent care to exclude other causes, including infection. Do not assume a known scan finding explains every new symptom.
Sudden calf swelling or breathlessness also requires the appropriate urgent pathway rather than waiting for a routine injection consultation. Call 999 for a medical emergency. New symptoms should be assessed on their own merits.
Why might an X-ray miss some loose bodies?
An X-ray can show larger nodules when they have calcified or formed bone. Smaller cartilage bodies or those that have not hardened may not be obvious. A normal or inconclusive X-ray therefore does not always answer the question when symptoms persist.
MRI or CT can help define the joint lining and the extent and location of the bodies. The right test depends on the examination and the clinical question. An MRI is not automatically required for every painful knee, but a mechanical symptom or a suspicious report may change the pathway.
Ask whether the imaging suggests primary disease, secondary bodies from arthritis or another explanation. If the diagnosis is uncertain, a specialist may need to review the actual images rather than rely on a short report summary.
What does treatment involve?
For primary synovial chondromatosis, AAOS describes surgery to remove the cartilage bodies, with consideration of removing some or all of the affected synovium. Surgery may be arthroscopic or open, depending on the extent and location of the disease.
The exact operation is individual. Removing only loose bodies and treating the abnormal lining are not identical approaches, and the recurrence discussion belongs with the surgeon. For secondary disease, the underlying joint damage also influences treatment.
A pain-management or rehabilitation plan may support function, but it does not physically remove a cartilage nodule. A useful consultation should distinguish symptom control from treatment of the structural problem so that expectations are clear from the start.
Can PRP dissolve the loose bodies?
PRP is not a method of removing loose bodies or excising abnormal synovium. The AAOS pathway for primary synovial chondromatosis is surgical; it does not establish PRP as a treatment for the nodules.
If an injection is discussed for a separate coexisting condition, the clinician should explain that distinction explicitly. Improvement in pain would not prove that loose bodies had gone or that the underlying synovial process had resolved.
Do not transfer a study in knee osteoarthritis to synovial chondromatosis simply because both involve the same joint. They have different treatment questions. Choosing an assessment before an injection helps avoid paying for a pathway that cannot answer the main problem.
Why is follow-up important?
Synovial chondromatosis can recur after treatment. AAOS describes regular follow-up to look for recurrence and progression of joint damage. The follow-up schedule depends on the individual case and what was found at treatment.
Ask what new swelling, locking or loss of movement should prompt earlier review. Ask also what rehabilitation and activity changes are recommended. Returning to sport or demanding work should be planned around recovery rather than an arbitrary date taken from another patient's experience.
Getting useful advice in London
Arrange a review of the symptoms and scan findings if you want help identifying the appropriate care route. Have the report, scan access, previous operations and any injection history ready. The clinician and appointment format should match the problem; availability and the complete fee are confirmed individually.
The best outcome from the first appointment may be a clear orthopaedic referral rather than an injection. A coordinated plan should explain the likely diagnosis, any remaining uncertainty, whether further imaging is needed and who is responsible for follow-up.
Your next step
If a report mentions synovial chondromatosis, do not read it as a PRP prescription. Ask for a plan that addresses the loose bodies and joint lining. Seek urgent care for serious new symptoms rather than waiting for a routine enquiry reply.
Sources and evidence limits
American Academy of Orthopaedic Surgeons: Synovial chondromatosis. Patient guidance on primary and secondary disease, imaging, surgery and recurrence. This is not evidence for PRP efficacy in this condition.
Prepared 3 November 2026. General patient information, not an individual diagnosis or surgical recommendation.